Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 17Active not recruiting 9Suspended 2Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 6Gastrointestinal 6Genitourinary 5Breast 4Sarcoma 3Myeloid 3CNS 3Tumor-Agnostic 2Dermatologic 2Thoracic 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Neoplasm Metastasis 2

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2E 7107 2Biopsy 2trastuzumab deruxtecan 1neratinib 1ipatasertib 1eniluracil 1Topotecan 1Taxes 1Surveys and Questionnaires 1Standard of Care 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Paclitaxel 1Maltose 1Magnetic Resonance Imaging 1Fluorodeoxyglucose F18 1Flucytosine 1Drug Implants 1Cyclophosphamide 1Cell Count 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Specimen Handling × Tumor-Agnostic × Clear all
NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI)

Phase 1 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡